We evaluated a series of Brazilian BC patients from diverse regions of the country that were studied in a single laboratory facility for likely pathogenic/pathogenic variants (PV) and variants of unknown significance (VUS) in BRCA1/2 and other BC susceptibility genes (ATM, BARD1, CDH1, CHEK2...
Epidemiology and Risk FactorsIt is estimated that, in the U.S., MBC will be diagnosed in 2,650 patients and cause 530 deaths in 2021.3 The lifetime risk of breast cancer (BC) in men is significantly lower than in women (1:1,000 vs. 1:8, respectively).1 As with other malignancies...
7. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr 4. doi: 10.3322/caac.21834. 8. National Cancer Inst...
7. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr 4. doi: 10.3322/caac.21834. 8. National Cancer Institute. Surveillance, Epidemiology and End Results Program. Available at: ...
Article Open access Published: 07 December 2022 Breast cancer prevention by short-term inhibition of TGFβ signalingMaša Alečković, Simona Cristea, Carlos R. Gil Del Alcazar, Pengze Yan, Lina Ding, Ethan D. Krop, Nicholas W. Harper, Ernesto Rojas Jimenez, Donghao Lu, Anu...
Breast cancer is the most common cancer among women in 157 out of 185 countries, leading to 670,000 deaths globally in 2022 [1]. The wide-reaching impacts of breast cancer, including its diverse costs and challenges across financial, physical, emotional, and societal spheres, extend beyond ind...
Review ArticleMale Breast Cancer: An Updated Review of Epidemiology,Clinicopathology, and TreatmentGuoliang Zheng1and Jose Pablo Leone21 Department of Medicine, St Elizabeth Medical Center, A Teaching Hospital of Boston University, 736 Cambridge Street, Boston,MA, USA2 Dana Farber Cancer Institute, 45...
Epidemiology of Breast Cancer Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early Breast cancer. Breast (Edinburgh Scotland). 2022;62(Suppl 1):12–s16. https://doi.org/10.1016/j.breast.2022.01.006. Article Google Scholar Petruolo O, Sevilimedu V, Montagna G,...
Mechanisms driving the immunoregulatory function of cancer cells Article 30 January 2023 TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective Article 15 November 2022 References Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, ...
2022 年 8 月 5 日,FDA 基于 DESTINY-Breast04 试验批准了德曲妥珠单抗(Enhertu, T-Dxd,DS-8201a)用于治疗不可切除或转移性 HER2 低表达乳腺癌,这是首个批准用于 HER2-low 乳腺癌的新疗法,其主要是基于 2022 年 5 月 27 日在 ASCO 会议上公布的临床结果。